I n this edition of Circulation: Arrhythmia and Electrophysiology, Elayi and colleagues 1 examined mortality in patients from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study who received external (transthoracic) cardioversion shocks for atrial fibrillation (AF) compared with those who had not received cardioversion shocks. The AFFIRM trial studied 4060 patients with a history of AF and compared a strategy of rhythm control versus rate control. 2 The strategy of using antiarrhythmic drug therapy to maintain sinus rhythm did not improve all-cause mortality when compared with rate control. In this substudy analysis of AFFIRM, the association of cardioversion shocks and subsequent risk of death was determined using Cox proportional hazards modeling. The primary finding was that patients who received cardioversion shocks were not at higher risk of death compared with the patients who did not receive cardioversion shocks. Other than an association of cardioversion with cardiac hospitalizations, these neutral findings were independent of ejection fraction, numbers of cardioversion episodes, or history of permanent versus paroxysmal AF.
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It is important to emphasize that a Cox proportional hazards model examines association of variables and does not establish "cause and effect." 3 The finding in the study by Elayi et al that there was an association of having had a cardioversion episode and having been hospitalized for cardiac reasons illustrates this principal. For instance, the hospitalization could have been for the purpose of medical management of the patient's AF, during which AF was treated with cardioversion, or for exacerbation of a chronic cardiac condition that triggered AF and then required cardioversion. The data do not elucidate the specific reasons for the observed association.
The findings from this substudy of AFFIRM are relevant to the much broader debate about the association of implantable cardioverter-defibrillator (ICD) shocks with subsequent mortality. Post hoc analyses of data from the Multicenter Automatic Defibrillator Implantation Trial-II (MADIT II) and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) have raised concerns about the safety of shock therapy. 4 -7 In both of these large, prospective, randomized trials, the mortality risk as assessed by the Cox proportional hazards method was higher in patients who had ICD shock therapies than in those who did not. Over the study follow-up time period, the mortality risk for patients having shocks for ventricular fibrillation (VF) or ventricular tachycardia (VT) was 3-to 6-fold that of ICD patients not shocked for VT or VF. In addition, there was a 2-fold increased mortality risk associated with inappropriate ICD shocks. The majority of inappropriate shocks were due to either AF or another supraventricular arrhythmia detected in the high-rate ICD therapy zones.
The association of ICD shocks with an increase in subsequent mortality has led to a resurrection of animal research from the 1980s as a means to understand the findings in MADIT II and SCD-HeFT. 8, 9 An example is the elegant laboratory study of Jones and colleagues, 8 who showed that extreme high-voltage shocks delivered to single layers of chick embryo myocytes resulted in electroporation of the cell membrane and alteration of resting membrane potentials. These studies, as mechanistically intriguing as they are, do not translate well to the complex circumstances of a human cardiac arrest and the much lower shock strengths used in contemporary ICDs.
Rhythm, Shock, or Substrate?
Separating the potential harm directly related to shocks from the risk conferred by the rhythm triggering those shocks has been the subject of much discussion. All patients in AFFIRM had a history of AF. 1,2 Therefore, the study by Elayi and colleagues evaluates the potential adverse effect of the cardioversion shock independent of whether AF was or was not present as a competing risk. Their findings support the safety of clinically used transthoracic shocks for AF.
As noted by Elayi and colleagues, AF occurring in patients with heart failure (HF) is a known predictor of adverse outcome. 10, 11 Similarly, an ICD shock for high-rate AF may simply "identify" a higher-risk patient. A recent analysis from a large ICD patient database provides further important insights into the potential risk associated with the occurrence of inappropriate shocks. 12 In this study, 3814 patients who had an ICD shock for an appropriate or inappropriate cause were case-matched to patients who had not had an ICD shock over 25 months of follow-up. Mortality was increased for patients with shocks for VT/VF or AF but not for those with inappropriate ICD shocks for lead-artifact, oversensing, or non-AF supraventricular rhythms. These data support the hypothesis that the risk associated with ICD shock therapy is related to the underlying rhythm and not to the shock itself.
Myocardial function after a shock may relate to the "state" of the myocardium at the time of defibrillation. For instance, in an isolated rat heart model, adverse hemodynamic conse-The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. quences after epicardial defibrillation occurred only when coronary perfusion was not maintained during VF. In contrast, measures of adverse cardiac function were not observed when coronary perfusion was maintained. 13, 14 Thus, the cellular environment of the ischemic and hypoperfused, fibrillating ventricle was the dominant cause of altered hemodynamic function.
The recent debate over shock-induced myocardial dysfunction notwithstanding, we should be very cautious not to discard a true life-saving therapy in exchange for a fashionable hypothesis. Most patients treated with an ICD for VT or VF live to see another day, and most do so for years. 4, 5 Without an ICD, a patient with VF or unstable high-rate VT would become 1 of the 700 to 1000 daily victims of sudden cardiac death in the United States. 15 Indeed, the mortality benefit of ICD therapy in MADIT II and SCD-HeFT was solely due to a reduction in arrhythmic mortality. 16, 17 Furthermore, a subsequent risk analysis performed in SCD-HeFT demonstrated that the moderately ill patient with HF (versus end-stage HF) had the most to gain from ICD therapy, because their mode of death is more likely to be arrhythmic rather than from progressive HF. 18 The occurrence of highrate VT or VF no doubt reflects a more electrically unstable cardiac substrate that may be due to progression of underlying coronary artery disease with or without acute ischemia or from worsened HF for any cause. With little progress made in out-of-hospital survival rates since the late 1980s, we should champion ICD therapy for at-risk patients. The rhythms most likely to result in sudden cardiac death are those that are also most likely to require shocks to be terminated.
The results from the study by Elayi and colleagues are important. Their report provides reassurance that cardioversion for AF remains a safe procedure. Perhaps this study may also serve to defray the recent excessive anxiety over cardioversion/ defibrillation shocks used to terminate life-threatening ventricular arrhythmias.
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